Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jialin Li
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
ORCID:
0000-0002-6069-1822
Observed ORCID:
0000-0002-6069-1822
OpenAlex ID:
A5024691043
Functional significance of cholesterol metabolism in cancer: from threat to treatment
2023
·
Mingming Xiao
, Jin Xu
, et al.
·
Experimental & Molecular Medicine
·
274
PDF
Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)
2023
·
Jialin Li
, Si Shi
, et al.
·
Trials
·
8
PDF
Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
2022
·
Xiaomeng Liu
, Jiang Liu
, et al.
·
Translational Oncology
·
8
Topical application of Glauber’s salt accelerates the absorption of abdominal fluid after pancreatectomy
2024
·
Jialin Li
, Jie Hua
, et al.
·
BMC Surgery
·
4
PDF
SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation.
2026
·
Jin Xu
, Si Shi
, et al.
·
Journal of Clinical Oncology
·
3
HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma.
2026
·
Xianjun Yu
, Jin Xu
, et al.
·
Journal of Clinical Oncology
·
3
Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer
2026
·
Si Shi
, Miaoyan Wei
, et al.
·
Cancer Cell
·
2
Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study.
2026
·
Miaoyan Wei
, Si Shi
, et al.
·
Journal of Clinical Oncology
Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC).
2026
·
Si Shi
, Jin Xu
, et al.
·
Journal of Clinical Oncology
Abstract CT146: Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study
2026
·
Jialin Li
, Miaoyan Wei
, et al.
·
Cancer Research
Show more works
View as search
Works count:
10
Citation count:
302
H-index:
4
I10-index:
1
Year
Topic
Type